Crinetics, Alamar, Halozyme Report Earnings
Crinetics, Alamar, and Halozyme report better-than-expected Q2 financial results
As of Aug.
12, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down.
When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term.
An asset is typically considered overbought when the RSI is above 70, according to Pro.
Here’s the latest list of major overbought players in this sector.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) On Aug.
3, Crinetics Pharmaceuticals reported better-than-expected second-quarter financial results.
The company’s stock gained around 91% over the past six months and has a 52-week high of $84.38.
RSI Value: 90.6 CRNX Price Action: Shares of Crinetics Pharmaceuticals rose 0.3% to close at $84.36 on Tuesday.
Edge Stock Ratings: 98.56 Momentum score.
Alamar Biosciences Inc (NASDAQ: ALMR ) On Aug.
10, Alamar Biosciences reported better-than-expected second-quarter financial results. “We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year,” said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. “With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters.” The company’s stock gained around 35% over the past five days and has a 52-week high of $38.54.
RSI Value: 86.8 ALMR Price Action: Shares of Alamar Biosciences jumped 30.7% to close at $36.57 on Tuesday.
Halozyme Therapeutics, Inc. (NASDAQ: HALO ) On Aug.
6, Halozyme Therapeutics reported better-than-expected second-quarter financial results and raised its FY26 guidance above estimates. “We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues,” said Dr.
Helen Torley, President and Chief Executive Officer.
The company’s stock gained around 22% over the past five days and has a 52-week high of $104.78.
RSI Value: 86 HALO Price Action: Shares of Halozyme Therapeutics closed at $102.62 on Tuesday.
Unlock the rest of the BZ Edge Rankings and see how top stocks stack up.
Photo via Shutterstock